Page 305 - 2022_01-Haematologica-web

Letters to the Editor
CLL. Blood Adv. 2021;5(16):3134-3146.
7. Allan JN, Patel K, Mato AR, et al. Ongoing results of a phase 1B/2 dose-
escalation and cohort-expansion study of the selective, noncovalent, reversible bruton's tyrosine kinase inhibitor, vecabrutinib, in B-cell malig- nancies. Blood. 2019;134(Supplement_1):3041.
8. Herman SE, Mustafa RZ, Gyamfi JA, et al. Ibrutinib inhibits BCR and NF-kB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL. Blood. 2014;123(21):3286-3295.
9. Patel V, Balakrishnan K, Bibikova E, et al. Comparison of acalabrutinib, a selective Bruton tyrosine kinase inhibitor, with ibrutinib in chronic lym- phocytic leukemia cells. Clinl Cancer Res. 2017;23(14):3734-3743.
10. Ponader S, Burger JA. Bruton's tyrosine kinase: from X-linked agamma- globulinemia toward targeted therapy for B-cell malignancies. J Clin Oncol. 2014;32(17):1830.
11. Neel BG, Gu H, Pao L. The ‘Shp'ing news: SH2 domain-containing tyro- sine phosphatases in cell signaling. Trends Biochem Sci. 2003;28(6):284- 293.
12. Araki T, Nawa H, Neel BG. Tyrosyl phosphorylation of Shp2 is required for normal ERK activation in response to some, but not all, growth fac- tors. J Biol Chem. 2003;278(43):41677-41684.
13.Kondo K, Shaim H, Thompson PA, et al. Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD- L1 pathway. Leukemia. 2018;32(4):960-970.
14. 15. 16.
Loh C-Y, Arya A, Naema AF, et al. Signal transducer and activator of tran- scription (STATs) proteins in cancer and inflammation: functions and therapeutic implication. Front Oncol. 2019;9:48.
Rui L, Drennan AC, Ceribelli M, et al. Epigenetic gene regulation by Janus kinase 1 in diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A. 2016;113(46):E7260-E7267.
Estupiñán HY, Wang Q, Berglöf A, et al. BTK gatekeeper residue varia- tion combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib. Leukemia. 2021;35(5):1317-1329.
haematologica | 2022; 107(1)
297